Over the years, Ethypharm has leveraged its expertise to become a leading mid-size global specialty pharmaceutical company. Today, we manufacture and provide essential medicines, focusing on Hospital Injectables, Central Nervous System (severe pain and addiction).
Founded in 1977, Ethypharm quickly became a European leader in drug delivery and oral modified-release formulations, developing technologies such as extended-release micro-granules and orodispersible tablets. These innovations have enhanced the administration and the absorption of active ingredients.
During this period, Ethypharm relied exclusively on commercial partnerships, initially in France before expanding across Europe, North America, and China.
With the rise of generic medicines in the early 2000s, Ethypharm applied its expertise to develop complex generics requiring advanced formulation and bioequivalence solutions. Products such as omeprazole, buprenorphine, fenofibrate, and esomeprazole were key milestones.
By 2010, Ethypharm strengthened its focus on pain management and addiction treatment, building on its existing expertise in these therapeutic areas.
The Group also established a solid presence in China, further expanding its international reach.
2015 was a turning point for Ethypharm, as it took the company from a strategic partnership-based model to a direct commercialization model. The Group began selling its morphine treatments directly in France and the UK.
Ethypharm rapidly expanded its presence across Europe’s 5 largest pharmaceutical markets:
Today, 81% of Ethypharm’s revenue comes from its pharmaceutical sales, with 85% generated through direct sales in our 6 affiliates and 15% from distribution. The remaining 19% comes from our CDMO (Contract Development and Manufacturing Organization) activities, through partnerships with other pharmaceutical companies.
With a strong industrial and commercial foundation, Ethypharm continues its profitable growth, staying close to patients and healthcare professionals worldwide.
